. 2021 Mar 5;11(2):543–553. doi: 10.1007/s13555-021-00499-8

Table 2.

Reasons for discontinuation of therapy (N = 426)

Reasons for drug discontinuation^a	Number (%)
Ineffectiveness	280 (65.7%)
From the 16th week^b	251 (89.6%)
Until the 16th week^b	29 (10.4%)
Adverse events^c	75 (17.6%)
Non-compliance	31 (7.3%)
Deaths^d	2 (0.5%)

^a52 patients (12.2%) did not have a reason listed

^b% calculated from the number of patients citing ineffectiveness

^c6 patients (8.0%) had malignancy (Hodgkin's lymphoma, kidney cancer, colorectal cancer, thyroid cancer and two prostate cancers); 4 patients (5.3%) had infection (recurrent infections); 3 patients (4.0%) had neurological diseases (Parkinson's disease, multiple sclerosis and vertigo); 3 patients (4.0%) had diseases of the heart and blood vessels (coronary heart disease and two 2 strokes); 2 patients (2.7%) had liver disease (hepatopathy); 1 patient (1.3%) had psychiatric illness (manic disorder); 1 patient (1.3%) had kidney disorder (renal insufficiency); 2 patients (2.7%) had other AE (cholecystolithiasis and rash of unclear etiology); 53 patients (70.7%) did not have the AE specified

^dBoth patients had two reasons for discontinuation—death and AE (in both cases it was a sudden death caused by pulmonary embolism and myocardial infarction)